Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Payzone

Rank: Mail Room [?]

Points: 198 [?]

Votes: 6 Score: 4.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

in response to

Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

KOO-KOO2

posted on Jan 26, 2023 11:32AM

I do not work in the biotech field, I am not a medical doctor or scientist.

When I read the definitions of these two cancers, "castration resistant" means hormone therapy is no longer effective while "hormone sensitive" means hormone therapy is effiective.

The Clinical trials specifiy this cancer type in the "conditions" section so I think they are different because they are targeting two different cancer conditions.